ASCO 23 explored novel anti-cancer agents in the genitourinary space. The future of oncology is etching closer daily. In this episode, Michael and Josh dissect ertafitinib, an FGFR inhibitor used in bladder cancer, talazoparib in prostate cancer and immunotherapy and TKI combinations in renal cell cancer. All these studies reflect the desire to target cancers further with some astonishing results.
Studies
THOR: https://meetings.asco.org/abstracts-presentations/217894
PEACE-1: https://meetings.asco.org/abstracts-presentations/218388
TALAPRO-2: https://meetings.asco.org/abstracts-presentations/222733
RENAL CELL CARCINOMA: https://meetings.asco.org/2023-asco-annual-meeting/15007?presentation=219853#219853
Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us atinquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
